We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells

By LabMedica International staff writers
Posted on 15 May 2024
Print article
Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)
Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)

Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations involved, typically require invasive biopsies, which can cause harm. Now, a research team has developed a new method to utilize ultrasound for gently extracting this genetic information.

Researchers at the University of Alberta (Edmonton, AB, Canada) have been investigating the use of intense ultrasound in releasing biological indicators of disease, or biomarkers, from cells. These biomarkers include elements like miRNA, mRNA, DNA, and various genetic mutations, all of which are critical for identifying the cancer type and guiding treatment decisions. The ultrasound technique releases these biomarkers from the cells into the bloodstream, where they reach concentrations high enough to be detected. This enables oncologists to identify and track the cancer's status or response to treatment through blood samples instead of invasive biopsies, making the process less painful and more cost-effective.

The application of ultrasound has proven to enhance the presence of genetic and vesicle biomarkers in blood samples by more than 100 times. The researchers successfully identified panels of tumor-specific and now epigenetic mutations that previously could not be detected in blood samples. This method is not only effective but also more affordable than traditional tests. They noted that ultrasound-enhanced blood tests could be performed at a cost similar to that of a COVID test, a significant reduction from the usual USD 10,000 per test.

Furthermore, the research team explored using intense ultrasound to liquefy small tissue samples for easier biomarker detection. This liquefied tissue can be collected from blood samples or via fine-needle syringes, which are considerably less invasive than traditional core-needle biopsies. These advancements in cancer detection technology could lead to earlier diagnosis and treatment, offering healthcare providers flexibility in managing treatment efficacy without the high costs and risks typically associated with frequent biopsies.

“We hope that our ultrasound technologies will benefit patients by providing clinicians a new kind of molecular readout of cells and tissues with minimal discomfort,” said Roger Zemp from the University of Alberta who led the team.

Related Links:
University of Alberta


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.